Xiaodong Wang

Zhejiang Provincial Key Laboratory For Accurate Diagnosis And Treatment Of Chronic Liver Diseases
Wenzhou, 325035, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Double-target responsive FRET sensor based on DNA tetrahedron for robust detection of liver fibrosis-related mRNAs in activated hepatic stellate cells.

Double-target responsive FRET sensor based on DNA tetrahedron for robust detection of liver fibrosis-related mRNAs in activated hepatic stellate cells.

Journal: Biosensors & bioelectronics

Published: December 29, 2025

mPEG-NH2/2-FPBA/TubA exerts anti-hepatocellular carcinoma activity by targeting ABCF1-K430la through the KDM3A-H3K9me2-HIF1A axis.

mPEG-NH2/2-FPBA/TubA exerts anti-hepatocellular carcinoma activity by targeting ABCF1-K430la through the KDM3A-H3K9me2-HIF1A axis.

Journal: Colloids and surfaces. B, Biointerfaces

Published: May 25, 2025

The utility of P-I-R classification in predicting the on-treatment histological and clinical outcomes of patients with hepatitis B and advanced liver fibrosis.

The utility of P-I-R classification in predicting the on-treatment histological and clinical outcomes of patients with hepatitis B and advanced liver fibrosis.

Journal: Hepatology (Baltimore, Md.)

Published: December 20, 2022

Machine learning integrations develop an antigen-presenting-cells and T-Cells-Infiltration derived LncRNA signature for improving clinical outcomes in hepatocellular carcinoma.

Machine learning integrations develop an antigen-presenting-cells and T-Cells-Infiltration derived LncRNA signature for improving clinical outcomes in hepatocellular carcinoma.

Journal: BMC cancer

Published: August 11, 2022

Development and validation of a potential biomarker to improve the assessment of liver fibrosis progression in patients with chronic hepatitis B.

Development and validation of a potential biomarker to improve the assessment of liver fibrosis progression in patients with chronic hepatitis B.

Journal: Journal of medical virology

Published: June 08, 2022

Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B.

Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B.

Journal: Journal of hepatology

Published: March 01, 2022

A novel nomogram to predict evident histological liver injury in patients with HBeAg-positive chronic hepatitis B virus infection.

A novel nomogram to predict evident histological liver injury in patients with HBeAg-positive chronic hepatitis B virus infection.

Journal: EBioMedicine

Published: February 10, 2021

A novel focal adhesion related gene signature for prognostic prediction in hepatocellular carcinoma.

A novel focal adhesion related gene signature for prognostic prediction in hepatocellular carcinoma.

Journal: Aging

Published: December 21, 2020

Ubiquitously specific protease 4 inhibitor-Vialinin A attenuates inflammation and fibrosis in S100-induced hepatitis mice through Rheb/mTOR signalling.

Ubiquitously specific protease 4 inhibitor-Vialinin A attenuates inflammation and fibrosis in S100-induced hepatitis mice through Rheb/mTOR signalling.

Journal: Journal of cellular and molecular medicine

Published: September 08, 2020

Unreliable Estimation of Fibrosis Regression During Treatment by Liver Stiffness Measurement in Patients With Chronic Hepatitis B.

Unreliable Estimation of Fibrosis Regression During Treatment by Liver Stiffness Measurement in Patients With Chronic Hepatitis B.

Journal: The American journal of gastroenterology

Published: August 20, 2020

A Novel Noninvasive Program for Staging Liver Fibrosis in Untreated Patients With Chronic Hepatitis B.

A Novel Noninvasive Program for Staging Liver Fibrosis in Untreated Patients With Chronic Hepatitis B.

Journal: Clinical and translational gastroenterology

Published: April 30, 2019

MiR-544 promotes immune escape through downregulation of NCR1/NKp46 via targeting RUNX3 in liver cancer.

MiR-544 promotes immune escape through downregulation of NCR1/NKp46 via targeting RUNX3 in liver cancer.

Journal: Cancer cell international

Published: October 20, 2017

Showing 1-12 of 16

Last Updated: 09/26/2026